A204840 Stock Overview
GL Pharm Tech Corp. suministra medicamentos genéricos y tecnología de formulación de medicamentos modificados incrementalmente (IMD) a empresas farmacéuticas de Corea del Sur.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GL Pharm Tech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,283.00 |
| 52 Week High | ₩1,830.00 |
| 52 Week Low | ₩704.00 |
| Beta | 1.11 |
| 1 Month Change | -3.61% |
| 3 Month Change | 8.91% |
| 1 Year Change | 62.82% |
| 3 Year Change | -11.52% |
| 5 Year Change | -60.28% |
| Change since IPO | -81.38% |
Recent News & Updates
Shareholder Returns
| A204840 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -5.9% | -5.8% | -1.5% |
| 1Y | 62.8% | 10.1% | 7.5% |
Rentabilidad frente al sector: A204840 superó al sector KR Pharmaceuticals , que obtuvo un rendimiento del 17.5% el año pasado.
Rentabilidad vs. Mercado: A204840 superó al mercado KR, que obtuvo un rendimiento del 9.8% el año pasado.
Price Volatility
| A204840 volatility | |
|---|---|
| A204840 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Precio estable de las acciones: A204840 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de A204840 (8%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 22 | Hun-Sik Wang | https://www.glpt.co.kr |
GL Pharm Tech Corp. suministra medicamentos genéricos y tecnología de formulación de medicamentos modificados incrementalmente (IMD) a empresas farmacéuticas de Corea del Sur. La empresa ofrece IMD para gastritis, antidepresivos, anorexígenos y antibióticos. También suministra medicamentos genéricos para enfermedades cardiovasculares, urología, dolor, antiinfecciosos, enfermedades gástricas, diabetes, enfermedades del sistema nervioso central, enfermedades respiratorias, trasplantes y otras áreas.
GL Pharm Tech Corp. Fundamentals Summary
| A204840 fundamental statistics | |
|---|---|
| Market cap | ₩98.41b |
| Earnings (TTM) | -₩3.75b |
| Revenue (TTM) | ₩26.03b |
3.8x
P/S Ratio-26.3x
P/E RatioIs A204840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A204840 income statement (TTM) | |
|---|---|
| Revenue | ₩26.03b |
| Cost of Revenue | ₩17.35b |
| Gross Profit | ₩8.68b |
| Other Expenses | ₩12.43b |
| Earnings | -₩3.75b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -48.87 |
| Gross Margin | 33.35% |
| Net Profit Margin | -14.40% |
| Debt/Equity Ratio | 143.5% |
How did A204840 perform over the long term?
See historical performance and comparison